Deutsche Bank AG Grows Stock Holdings in ProKidney Corp. $PROK

Deutsche Bank AG increased its position in ProKidney Corp. (NASDAQ:PROK) by 49.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 86,337 shares of the company’s stock after buying an additional 28,546 shares during the period. Deutsche Bank AG’s holdings in ProKidney were worth $76,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of PROK. ProShare Advisors LLC lifted its position in shares of ProKidney by 57.3% in the fourth quarter. ProShare Advisors LLC now owns 30,879 shares of the company’s stock valued at $52,000 after acquiring an additional 11,250 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of ProKidney during the fourth quarter worth about $88,000. Wells Fargo & Company MN raised its stake in ProKidney by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 54,098 shares of the company’s stock valued at $91,000 after purchasing an additional 18,431 shares during the period. BNP Paribas Financial Markets purchased a new position in ProKidney in the 4th quarter worth approximately $110,000. Finally, JPMorgan Chase & Co. lifted its holdings in ProKidney by 41.8% in the 4th quarter. JPMorgan Chase & Co. now owns 66,415 shares of the company’s stock worth $112,000 after purchasing an additional 19,585 shares in the last quarter. 51.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PROK shares. UBS Group increased their price objective on shares of ProKidney from $4.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, July 15th. Zacks Research lowered shares of ProKidney from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Guggenheim reaffirmed a “buy” rating and set a $7.00 target price (up from $6.00) on shares of ProKidney in a research note on Monday, July 14th. Wall Street Zen upgraded shares of ProKidney from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, Bank of America downgraded shares of ProKidney from a “neutral” rating to an “underperform” rating and dropped their price objective for the company from $3.00 to $1.00 in a report on Monday, June 30th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.25.

ProKidney Stock Down 5.6%

Shares of NASDAQ:PROK opened at $2.36 on Tuesday. The firm has a fifty day simple moving average of $2.49 and a two-hundred day simple moving average of $1.45. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $7.13. The stock has a market capitalization of $694.50 million, a P/E ratio of -4.14 and a beta of 1.74.

ProKidney (NASDAQ:PROK) last announced its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The business had revenue of $0.22 million for the quarter. On average, analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current year.

Insider Transactions at ProKidney

In other news, insider Darin J. Weber sold 103,480 shares of the firm’s stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.02, for a total value of $312,509.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 41.49% of the stock is currently owned by company insiders.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.